8-KMaterial AgreementsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (Nov 17, 2016)

Filed November 17, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed a Form 8-K on November 16, 2016, to report on the entry into a material definitive agreement related to the issuance of senior notes. The company has agreed to issue a significant amount of debt, totaling €4 billion across three tranches with varying interest rates and maturity dates: €1.4 billion of 0.375% senior notes due 2019, €1.45 billion of 1.375% senior notes due 2024, and €0.75 billion of 2.125% senior notes due 2028. This issuance is part of a pre-established shelf registration statement filed with the SEC, indicating AbbVie's strategic use of capital markets to fund its operations or future growth initiatives. The specific terms of the debt issuance, including the agreements with underwriters, trustee, paying agent, and registrar, were detailed in the filing. Investors should view this as a proactive financial management move, likely aimed at diversifying funding sources or managing debt maturities.

Key Highlights

  • 1AbbVie entered into an Underwriting Agreement on November 14, 2016, to issue senior notes.
  • 2The total aggregate principal amount of debt securities to be issued is €4 billion.
  • 3The issuance includes €1.4 billion of 0.375% senior notes due 2019.
  • 4The issuance includes €1.45 billion of 1.375% senior notes due 2024.
  • 5The issuance includes €0.75 billion of 2.125% senior notes due 2028.
  • 6The debt issuance is registered under AbbVie's existing shelf registration statement on Form S-3.
  • 7Supplemental Indenture No. 4 and an Agency Agreement were entered into on November 17, 2016, detailing the terms of the notes and agency roles.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the entry into a material definitive agreement concerning the issuance and sale of senior notes. This signals a significant financing activity undertaken by AbbVie.

AbbVie is issuing a total of €4 billion in senior notes across three series: €1.4 billion of 0.375% notes due 2019, €1.45 billion of 1.375% notes due 2024, and €0.75 billion of 2.125% notes due 2028. These are senior notes with specific coupon rates and maturity dates.

This debt issuance is part of AbbVie's broader capital management strategy, leveraging its existing shelf registration statement. It likely aims to secure long-term funding, manage its debt profile, or finance ongoing operations and strategic initiatives. The specific use of proceeds is not detailed in this 8-K, but such issuances typically support corporate objectives.

The key parties involved include AbbVie as the issuer, several major financial institutions acting as underwriters (Barclays Bank PLC, Deutsche Bank AG, J.P. Morgan Securities plc, Merrill Lynch International, and Morgan Stanley & Co. International plc), and U.S. Bank National Association as the trustee, paying agent, and registrar.